SM
Therapeutic Areas
Calithera Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CB-1158 (INCB001158) | Advanced/Metastatic Solid Tumors | Phase 1/2 |
| CB-839 (Telaglenastat) | Renal Cell Carcinoma | Phase 2 |
| CB-280 | Cystic Fibrosis | Preclinical/Phase 1 |
Leadership Team at Calithera Biosciences
CM
Christopher Molineaux
Former President & CEO
GG
Gary G. Lyons
Chairman of the Board
MD
Mikael Dolsten
Former Board Member
AM
Arthur M. Pappas
Board Member
JS
J. Scott Garland
Former Board Member
KO
Keith Orford
Chief Medical Officer
MM
Michael Morrissey
Former Chief Scientific Officer